Brodalumab is a prescription medication used to treat moderate to severe plaque psoriasis in adults. It is a monoclonal antibody that works by blocking a protein called interleukin-17 (IL-17) that is involved in the inflammation that causes psoriasis. Brodalumab is available as an injection that is given under the skin every two weeks. Common side effects include injection site reactions, upper respiratory tract infections, nasopharyngitis, and headache.
Brodalumab, sold under the brand name Kyntheum, is a biologic medication used to treat moderate to severe plaque psoriasis in adults. Here's a breakdown of its key aspects:
What it treats:
- Brodalumab is specifically indicated for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy (medication that affects the entire body) and who have failed to respond adequately to or are intolerant to other therapies like phototherapy (light therapy) or other systemic medications.
How it works:
- Brodalumab belongs to a class of medications called interleukin-17 (IL-17) inhibitors. These medications work by targeting and blocking the activity of interleukin-17, a specific protein involved in the inflammatory processes of psoriasis. By blocking IL-17, brodalumab helps to reduce inflammation and improve symptoms like redness, scaling, and thickening of the skin.
How it's administered:
- Brodalumab is administered as a subcutaneous injection (injection under the skin) by a healthcare professional. The typical starting dosage is 210mg injected every two weeks for the first 3 doses, followed by 140mg injections every 4 weeks thereafter.
- The duration of treatment depends on individual response and is determined by the healthcare professional.
Important considerations:
- Brodalumab can cause various side effects, including:
- Upper respiratory tract infections (like colds or sinus infections)
- Headache
- Fatigue
- Joint pain
- Mouth ulcers
- Injection site reactions (pain, redness, swelling)
- Fungal infections: Brodalumab can increase the risk of developing fungal infections, such as candidiasis (thrush).
- Suicidal thoughts and behaviors: There is a warning label for brodalumab regarding the risk of suicidal thoughts and behaviors, particularly in the first few months of treatment or after a dosage change. It is crucial to be aware of this risk and to seek immediate medical attention if you experience any new or worsening symptoms of depression, anxiety, or changes in mood or behavior.
- Pregnancy and breastfeeding: Brodalumab is not recommended for use during pregnancy or breastfeeding due to the potential risk of harm to the developing fetus or newborn baby.
Disclaimer: This information is provided for general knowledge only and should not be taken as medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment specific to your situation. They can determine if brodalumab is an appropriate treatment option for your psoriasis and guide you on its safe and effective use.